Nasal drug delivery - Possibilities, problems and solutions

Journal of Controlled Release

Volumn 87, Issue 1-3, 2003, Pages 187-198

  Illum, Lisbeth ^a,b  

^a Drug Delivery and Clinical Research Centre Ltd   (United Kingdom)

^b IDentity   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; APOMORPHINE; ARGININE; CHITOSAN; CHOLECYSTOKININ OCTAPEPTIDE; CORTICOTROPIN; DIPHTHERIA VACCINE; DNA VACCINE; HYDROXOCOBALAMIN; INFLUENZA VACCINE; INSULIN; MELATONIN; MORPHINE DERIVATIVE; PEPTIDE DERIVATIVE; PERTUSSIS VACCINE; POLYSACCHARIDE; VASOPRESSIN;

BRAIN; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; FEASIBILITY STUDY; GUINEA PIG; HUMAN; MEMBRANE; NONHUMAN; NOSE; NOSE CAVITY; PLASMID; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; NASAL CAVITY; PHARMACEUTICAL PREPARATIONS; VACCINES;

EID: 0037459005     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00363-2     Document Type: Conference Paper

References (46)

1. Illum L. Bioadhesive formulations for nasal peptide delivery. Mathiowitz E., Lehr C.M., Chickering D. Drug Delivery-issues in Fundamentals, Novel Approaches and Development. 1998;507-539 Marcel Dekker, New York.
2. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal system for vaccines. Adv. Drug Del. Rev. 51:2001;81-96.
3. Striebel H.W., Kramer J., Luhman I., Rohierse-Hohler I., Rieger A. Pharmakokinetische studie zur intranasalen gabe von fentanyl. Der Schmerz. 7:1993;122-125.
4. Moore K.H., Hussey E.K., Shaw S., Fuseau E., Duquesnoy C., Pakes G.E. Safety, tolerability and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia. 17:1997;541-550.
5. McMartin C., Hutchinson L.E.F., Hyde R., Peters G.E. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 76:1987;535-540.
6. Madara J.L., Dharmsathaphorn K. Occluding junction structure function relationship in a cultured epithelial monolayer. J. Cell Biol. 101:1985;2124-2133.
7. Grass G.M., Robinson J.R. Mechanisms of corneal drug penetration II: Ultrastructure analysis of potential pathways for drug movement. J. Pharm. Sci. 77:1988;15-23.
8. Inagaki M., Sakakura Y., Itoh J., Ukai K., Miyoshi Y. Macromolecular permeability of the tight junction of the human nasal mucosa. Rhinology. 23:1985;213-221.
9. Illum L., Jorgensen H., Bisgaard H., Krogsgaard O., Rossing N. Bioadhesive microspheres as a potential nasal drug delivery system. Int. J. Pharm. 39:1987;189-199.
10. Soane R.J., Frier M., Perkins A.C., Jones N.S., Davis S.S., Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. 178:1999;55-65.
11. Harris A.S., Nilsson I.M., Wagener Z.G., Alkner U. Intranasal administration of peptides: Nasal deposition, biological response and absorption of desmopressin. J. Pharm. Sci. 75:1986;1085-1088.
12. Lee V.H.L. Enzymatic barriers to peptide and protein absorption. CRC Crit. Rev. Ther. Drug Carrier Syst. 5:1988;69-97.
13. Hussain A., Faraj J., Aramaki Y., Truelove J.E. Hydrolysis of leucine enkephalin in the nasal cavity of the rat-a possible factor in the low bioavailability of nasally administered peptides. Biochem. Biophys. Res. Commun. 133:1985;923-928.
14. Kashi S.D., Lee V.H.L. Enkephalin hydrolysis in homogenates of various absorptive mucosae of the albino rabbit: similarities in rates and involvement of aminopeptidases. Life Sci. 38:1986;2019-2028.
15. Jorgensen L., Beckgaard E. Intranasal permeation of thyrotropin-releasing hormone:in vitro study of permeation and enzymatic degradation. Int. J. Pharm. 107:1994;231-237.
16. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15:1998;1326-1331.
17. Artursson P., Lindmark T., Davis S.S., Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11:1994;1358-1361.
18. Dodane V., Khan M.A., Merwin J.R. Effect of chitosan on epithelial permeability and structure. Int. J. Pharm. 182:1999;21-32.
19. Behl C. Experiences and the potential of nasal drug delivery. March 23-24, 2000;Presentation to a Management Forum Meeting on Nasal Drug Delivery, London.
20. Illum L., Watts P., Fisher A.N., Hinchcliffe M., Norbury H., Jabbal-Gill I., Nankervis R., Davis S.S. Intranasal delivery of morphine. J. Pharmacol. Exp. Ther. 301:2002;1-10.
21. A. Wilcock, H. Pavis, J. Edgecombe, D. Carr, C. Manderson, A. Church, Nasal morphine for the treatment of breakthrough pain in cancer patients, J. Pain Sympt. Manag. (in press).
22. Illum L., Watts P., Fisher A.N., Jabbal-Gill I., Davis S.S. Novel chitosan based delivery systems for nasal administration of a LHRH-analogue. STP Pharm. 10:2000;89-94.
23. W.H. Frey, Interview, Reuters Health, 16th February (2001).
24. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11:2000;1-18.
25. S.C. Quay, Successful delivery of apomorphine to the brain following intranasal administration demonstrated in clinical study. PRNewswire. July 18th (2001).
26. Fehm H.L., Perras B., Smolnik R., Kern W., Born J. Manipulating neuropeptidergic pathways in humans: A novel approach to neuropharmacology. Eur. J. Pharmacol. 405:2000;43-54.
27. Perras B., Pannenborg H., Marchall L., Pietrowsky R., Born J., Fehm H.L. Beneficial treatment of age-related sleep disturbances with prolonged intranasal vasopressin. J. Clin. Psychopharmacol. 19:1999;28-36.
28. Perras B., Marshall L., Kohler G., Born J., Fehm H.L. Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans. Psychoneuroendocrinology. 24:1999;743-757.
29. Dahlin M., Bergman U., Jansson B., Bjork E., Brittebo E. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm. Res. 17:2000;737-742.
30. Pietrowsky R., Thieman A., Kern W., Fehm H.L., Bern J. A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin. Psychoneuroendocrinology. 21:1996;559-572.
31. Okuyama S. The first attempt at radioisotopic evaluation of the integrity of the nose-brain barrier. Life Sci. 60:1997;1881-1884.
32. Derad I., Willeke K., Pietrowsky R., Born J., Fehm H.L. Intranasal angiotensin II directly influences central nervous regulation of blood pressure. Am. J. Hypertens. 11:1998;971-977.
33. Fehm H.L., Smolnik R., Kern W., McGregor G.P., Bickel U., Born J. The melanocortin Melanocyte-stimulating hormone/adrenocorticotropin4-10 decreases body fat in humans. J. Clin. Endocrinol. Metab. 86:2001;1144-1148.
34. Kern W., Peters A., Fruehwald-Schultes B., Deininger E., Born J., Fehm H.L. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology. 74:2001;270-280.
35. FitzGerald D., Mrsny R.J. New approaches to antigen delivery. Crit. Rev. Ther. Drug Carr. Syst. 17:2000;1405-1412.
36. Cano F., Plotnicky-Guilquin H., Nguyen T.N., Liljeqvist S., Samuelson P., Bonnefoy J.-Y., Stahl S., Robert A. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunisation using live staphylococci with surface-displayed RSV-peptides. Vaccine. 18:2000;2743-2752.
37. Matsua K., Yoshikawa T., Asanuma H., Iwasaki T., Hagiwara Y., Chen Z., Kadowaki S., Tsujimoto H., Kurata T., Tamura S. Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin). Vaccine. 18:2000;2713-2722.
38. Belshe R.B., Mendelmn P.M., Treanor J., Gruber W.C., Piedra P., Bernstein D.I., Hayden F.G., Kotloff K., Zangwill K., Wolff M. The efficacy of live attenuated, cold adapted, trivalent, intranasal influenza virus vaccine in children. New Engl. J. Med. 338:1998;1405-1412.
39. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165:2000;4778-4782.
40. Jabbal-Gill I., Church A., Lin W., Illum L., McNeela E., Rappuoli R., Podda A., Giemza E., Lewis D., Mills K.H.G. An intranasal study of immunogenicity and tolerability of diphtheria vaccine (CRM197) in combination with chitosan in adult human volunteers. 2002;AAPS, Toronto, Canada.
41. M. Iqbal, W. Lin, I. Jabbal-Gill, S.S. Davis, M.W. Steward, L. Illum, Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice, Vaccine (in press).
42. Roy K., Mao H.-Q., Huang S.K., Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine peanut allergy model. Nat. Med. 5:1999;387-391.
43. Pietrowsky R., Struben C., Molle M., Fehm H.L., Born J. Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans. Psychiatry. 39:1996;332-340.
44. Kern W., Born J., Schreiber H., Fehm H.L. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes. 48:1999;557-563.
45. Smolnik R., Molle M., Fehm H.L., Born J. Brain potentials and attention after acute and subchronic intranasal administration of ACTH 4-10 and desacetyl-alpha-MSH in humans. Neuroendocrinology. 70:1999;63-72.
46. Merkus P. Nose To Brain. 26-27th March 2001;Management Forum Nasal Drug Delivery Symposium, London.